Certara is the leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development.
PRINCETON, NJ – Sept. 26, 2018 – Certara announced today the launch of its BaseCase Portal cloud-based platform, that allows for the rapid creation of fully-customizable mobile apps that connect live to mathematical models and algorithms, and help HCPs optimize treatment for individual patients.
PRINCETON, NJ – Sept. 13, 2018 – Certara announced today that it has acquired Pirana, a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
August 16, 2018 – Certara today announced the launch of D360 v10.5, the first in a series of releases focused on delivering biologic-relevant tools together with D360’s data access capabilities.
PRINCETON, NJ – Aug. 2, 2018 – Certara today reported that 95% of novel new drug approvals by the US Food and Drug Administration (FDA) in the first half of 2018 were supported by Certara software or services. Those results emphasize how much modeling and simulation has become an integral part of regulatory submissions and highlight Certara’s leadership role in the field.
PRINCETON, NJ – July 26, 2018 – Certara announced today that Clinical Pharmacology & Therapeutics has published its “Letter to the Editor” describing the important role that quantitative systems pharmacology can play in defining dosing criteria for first-in-human clinical trials, together with the European Medicines Agency’s response.
PRINCETON, NJ – June 14, 2018 – Certara was privileged to participate as a key member of the Medicines Development for Global Health development team to achieve FDA approval of moxidectin.
PRINCETON, NJ – June 5, 2018 – Certara today announced the launch of Phoenix 8.1.
PRINCETON, NJ – May 29, 2018 – Certara today announced its participation in 28 sessions at the Population Approach Group in Europe (PAGE) 2018 Annual Meeting. PAGE is a UK-based, nonprofit organization, which is committed to taking a population approach to data analysis.
PRINCETON, NJ – May 21, 2018 – Certara today announced the launch of Analytica Laser’s Market Access Radar™, a three times weekly market access intelligence briefing. This market access data is also available via an easily searchable web portal.
PRINCETON, NJ – Apr. 12, 2018 – Certara today announced that it has acquired Analytica Laser, a global research consultancy that uses health economics and outcomes research (HEOR) and real-world data to provide the highest level of scientific evidence of the value of medicines and health technologies.